PRINCIPALES PUBLICATIONS
DEPUIS 2019
Conditions of sleep restoration after smoking cessation: a systematic review
Mauries S, Rolland B, Malleyvas M, Catoire S, Zehani F, Sauvage K, Davido G, Lejoyeux M, Geoffroy PA.
Sleep Med Rev 2025. https://doi.org/10.1016/j.smrv.2024.102041
Lespine LF, François D, Haesebaert J, Delile JM, Savy M, Tubiana-Rey B, Naassila M, de Ternay J, Rolland B.
Front Public Health. 2024; 12:1466739. doi: 10.3389/fpubh.2024.1466739.
de Ternay J, Nohales L, Fort E, Pelloux S, Coste C, Leblanc P, Wallon M, Fassier JB, Rolland B.
Eur Addict Res. 2024; 1-22. doi: 10.1159/000542592
de Ternay J, Meley C, Guerin P, Meige S, Grelaud N, Rolland B, Chappuy M.
Int J Drug Policy. 2024; 135:104660. doi: 10.1016/j.drugpo.2024.104660.
Compared implementation of the long-acting buprenorphine treatment buvidal in four European countries.
Rolland B, Matheson C, Kaski A, Kosim M, Roncero C, Vorspan F.
Expert Opin Drug Deliv. 2024. doi: 10.1080/17425247.2024.2369756.
Impact of HCV cure on subsequent hospitalizations in people with mental disorders: Results from the French claims database.
Rolland B, Hallouche N, Lada O, Rabiéga P, Fouad F, Benabadji E, Pol S.
Psychiatry Res. 2024; doi: 10.1016/j.psychres.2024.116032.
Comparing methadone policy and practice in France and the US: Implications for US policy reform.
Englander H, Chappuy M, Krawczyck N, Bratberg J, Potee R, Jauffret-Roustide M, Rolland B.
Int J Drug Policy. 2024 Jun 14:129:104487.doi: 10.1016/j.drugpo.2024.104487
Chappuy M, Lack P, David B, Penavayre G, Thabourey D, Landulpho M, Plasse A, Icard C, Bailly F, Boutahra F, Pradat P, Maynard M, Jauffret-Roustide M, de Ternay J, Rolland B.
Harm Reduct J. 2023 Oct 16;20(1):149. doi: 10.1186/s12954-023-00887-7.
Chappuy M, Lack P, David B, Penavayre G, Thabourey D, Landulpho M, Plasse A, Icard C, Bailly F, Boutahra F, Pradat P, Maynard M, Jauffret-Roustide M, de Ternay J, Rolland B..
Harm Reduct J. 2023 Oct 16;20(1):149. doi: 10.1186/s12954-023-00887-7.
Five challenges in implementing cognitive remediation for patients with substance use disorders in clinical settings.
Maurage P, Rolland B, Pitel AL, d'Hondt F.
Neuropsychol Rev. 2024; 34(3):974-984. doi: 10.1007/s11065-023-09623-1
Association between cannabis use and symptom dimensions in schizophrenia spectrum disorders: an individual participant data meta-analysis on 3053 individuals.
Argote M, Sescousse G, Brunelin J, [...], Nourredine M, Rolland B.
eClinicalMedicine 2023; 8:64:102199.doi: 10.1016/j.eclinm.2023.102199.
Compared Profile of Late-Onset Versus Childhood-Onset ADHD: A Case-Control Study Among Treatment-Seeking Adult Patients.
Jurek L, Montègue S, Larrieu A, Icard C, Rolland B.
J Atten Disord. 2023; 11:10870547231191756. doi: 10.1177/10870547231191756.
Profile of patients with a positive HCV viral load in a large French psychiatric hospital (2019-2021): A case-control study.
Torres C, Bauer G, Aubriet S, Scholtes C, Bailly F, Maynard-Muet M, Pradat P, Pillot-Meunier F, Lespine LF, Rolland B.
J Viral Hepat. 2023; 30(10):830-833. doi: 10.1111/jvh.13875.
Touali R, Chappuy M, Berger-Vergiat A, Deletoille M, Ragonnet D, Rochet T, Poulet E, Tazarourte K, Haesebaert J, Michel P, Rolland B. Encéphale. 2023; doi: 10.1016/j.encep.2023.04.009.
de Ternay J, Larrieu A, Sauvestre L, Montègue S, Guénin M, Icard C, Rolland B.
Nutrients. 2022; 14(23), 4958; doi.org/10.3390/nu14234958
Longitudinal determinants of insomnia among patients with alcohol use disorder.
Bolstad I, Toft H, Lien L, Moe JS, Rolland B, Bramness JG.
Alcohol. 2022; S0741-8329(22)00116-1. doi: 10.1016/j.alcohol.2022.11.002.
Autonomic responses during Gambling: the Effect of Outcome Type and Sex in a large community sample of young adults.
Hultman C, Vadlin S, Rehn M, Sescousse G, Nilsson KW, Åslund C.
J Gambl Stud. 2022. doi: 10.1007/s10899-022-10118-6.
Antipsychotic prescribing practices in real-life (APPREAL study): Findings from the French National Healthcare System Database (2007–2017).
Rolland B, Dalon F, Gauthier N, Nourredine M, Bérard M, Carton L, Brousse G, Llorca PM, Jacoud F, Van Ganse E, Belhassen M. Front Psychiatry. 2022; doi.org/10.3389/fpsyt.2022.1021780
Association between formal thought disorder and cannabis use: a systematic review and meta-analysis.
Argote M, Sescousse G, Brunelin J, Fakra E, Nourredine M, Rolland B.
Schizophrenia (Heidelb). 2022; 8(1):78. doi: 10.1038/s41537-022-00286-0.
Adherence to opioid agonist therapy predicts uptake of direct-acting antivirals in people who use drugs: results from the French national healthcare database (the ANRS FANTASIO study).
Rolland B, Lions C, Di Beo V, Carrieri P, Authier N, Barré T, Delorme J, Mathurin P, Bailly F, Protopopescu C, Marcellin F. Harm Reduct J. 2022; 19(1):119. doi: 10.1186/s12954-022-00702-9.
Fovet T, Wathelet M, Benbouriche M, Benradia I, Roelandt JL, Thomas P, d'Hondt F, Rolland B.
Eur Addict Res. 2022; 28(5):368-376. doi: 10.1159/000526079.
Lespine LF, Bramness JG, Pignon B, Vaiva G, Thomas P, Roelandt JL, Benradia I, Amad A, Geoffroy PA, Rolland B.
Arch Womens Ment Health. 2022; 25(5):895-902. doi: 10.1007/s00737-022-01253-5.
What is the potential for abuse of lisdexamfetamine in adults? A preclinical and clinical literature review and expert opinion.
Carton L, Icick R, Weibel S, Dematteis M, Kammerer E, Batisse A, Rolland B; French coordination for adult ADHD. Expert Rev Clin Pharmacol 2022; 15(8):921-925. doi: 10.1080/17512433.2022.2112950.
Louvet A, Trabut JB, Moreno C, Moirand R, Aubin HJ, Ntandja Wandji LC, Nourredine M, Ningarhari M, Ganne-Carrié N, Pageaux GP, Bailly F, [...], Mathurin P, Rolland B; for the Groupe collaboratif AFEF-SFA Maladie du foie liée à l'alcool. Liver Int. 2022; 42(6):1330-1343. doi: 10.1111/liv.15221.
One-month alcohol abstinence national campaigns: a scoping review of the harm reduction benefits.
de Ternay J, Leblanc P, Michel P, Benyamina A, Naassila M, Rolland B.
Harm Reduct J. 2022; 19(1):24. doi: 10.1186/s12954-022-00603-x
Proportion and conditions of use of intranasal take-home naloxone kits: A retrospective study in two French outpatient addiction centers, 2016-2020.
Chappuy M, Fezzani L, Ragonnet D, Berger A, Duvernay N, Lack P, Rolland B.
Therapies. 2022; 77(5):581-584. doi: 10.1016/j.therap.2022.01.006.
Guiraud J, Addolorato G, Antonelli M, Aubin HJ, [...], Rolland B, Rotondo C, Scherrer B, Simon N, Skala K, Söderpalm B, Somaini L, Sommer WH, Spanagel R, Vassallo GA, Walter H, van den Brink W.
J Psychopharmacol. 2022; 36(10):1136-1145. doi: 10.1177/02698811221104063.
Chappuy M, Nourredine M, Clerc B, Fahmi M, Misslin P, Berthier M, Laloi L, Rolland B.
Fundam Clin Pharmacol. 2022; 36(2):448-452. doi: 10.1111/fcp.12726.
Tobacco-induced sleep disturbances: A systematic review and meta-analysis.
Catoire S, Nourredine M, Lefebvre S, Couraud S, Gronfier C, Rey R, Peter-Derex L, Geoffroy PA, Rolland B.
Sleep Med Rev. 2021; 60:101544. doi: 10.1016/j.smrv.2021.101544.
Chapron SA, Nourredine M, Dondé C, Haesebaert F, Micoulaud-Franchi JA, Geoffroy PA, Rolland B.
Fundam Clin Pharmacol. 2021; 36(1):4-15. doi: 10.1111/fcp.12710.
Validation of the French version of the Cannabis Use Disorder Identification Test-Revised and comparison with the Cannabis Abuse Screening Test for screening cannabis use disorder in a psychiatric sample.
Luquiens A, Berger-Viergat A, Larrieu A, Artigaud L, Fener C, Adamson S, Laprévote V, Rolland B.
Drug Alcohol Rev. 2021; 40(7):1334-1339. doi: 10.1111/dar.13298.
Laconi S, Palma-Alvarez RF, Stöver H, Padberg C, Jamin D, Meroueh F, Chappuy M, Roncero C, Rolland B.
Eur Addict Res. 2021; 27(5):326-331. doi: 10.1159/000511770.
Determinants of interest in extended-released buprenorphine: A survey among 366 French patients treated with buprenorphine or methadone.
Rolland B, Trojak B, Nourredine M, Bachellier J, Chappuy M, Bendimerad P, Kosim M, Hjelmström P, Meroueh F, Nubukpo P, Brousse G. Drug Alcohol Depend. 2021; 220:108492. doi: 10.1016/j.drugalcdep.2020.108492.
Dobre D, Schwan R, Jansen C, Schwitzer T, Martin O, Ligier F, Rolland B, [...], Leboyer M, Thomas P, Gorwood P, Laprevote V. Psychol Med. 2021; 1-9. doi: 10.1017/S0033291721001537.
Global Changes and Factors of Increase in Caloric/Salty Food Intake, Screen Use, and Substance Use During the Early COVID-19 Containment Phase in the General Population in France: Survey Study.
Rolland B, Haesebaert F, Zante E, Benyamina A, Haesebaert J, Franck N.
JMIR Public Health Surveill. 2020; 6(3):e19630. doi: 10.2196/19630.
Prolonged-release buprenorphine formulations: Perspectives for clinical practice
Chappuy M, Trojak B, Nubukpo P, Bachellier J, Bendimerad P, Brousse G, Rolland B.
Therapies. 2020; 75(5):397-406. doi: 10.1016/j.therap.2020.05.007.
Management of insomnia in alcohol use disorder.
Geoffroy PA, Lejoyeux M, Rolland B.
Expert Opin Pharmacother. 2020; 21(3):297-306. doi: 10.1080/14656566.2019.1705279.
Disparate regulatory status of methylphenidate for adults with ADHD across Europe.
Chappuy M, Boulanger A, Nourredine M, Fourneret P, Rolland B.
Lancet Psychiatry. 2020; 7(1):e1-e2. doi: 10.1016/S2215-0366(19)30482-1.
Management of insomnia in alcohol use disorder.
Meyrel M, Rolland B, Geoffroy PA.
Prog Neuropsychopharmacol Biol Psychiatry. 2020; 99:109831. doi: 10.1016/j.pnpbp.2019.109831.
France Grants an Approval to Baclofen for Alcohol Dependence.
Rolland B, Simon N, Franchitto N, Aubin HJ.
Alcohol Alcohol. 2020; 55(1):44-45. doi: 10.1093/alcalc/agz082.
Barré T, Marcellin F, Di Beo V, Delorme J, Rojas Rojas T, Mathurin P, Protopopescu C, Bailly F, Coste M, Authier N, Carrieri MP, Rolland B. Addiction. 2020; 115(3):573-582. doi: 10.1111/add.14820.
Pignon B, Sescousse G, Amad A, Benradia I, Vaiva G, Thomas P, Geoffroy PA, Roelandt JL, Rolland B.
Alcohol Alcohol. 2020; 55(1):112-120